Skip to search formSkip to main contentSkip to account menu

CRLX101

Known as: Cyclodextrin-Based Polymer-Camptothecin CRLX101 
A formulation of camptothecin, an alkaloid isolated from the Chinese tree Camptotheca acuminata, conjugated with to a hydrophilic, cyclodextrin-based… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

IT-101
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
CRLX101 plus olaparib in patients with metastatic castration-resistant prostate cancer.
TPS5096Background: Prostate cancer is the most commonly diagnosed cancer among men in the United States. While prostate cancer is… 
2016
2016
Abstract 3209: CRLX101, an investigational nanoparticle-drug conjugate of camptothecin, demonstrates synergy with immunotherapy agents in preclinical models
CRLX101, an investigational nanoparticle-drug conjugate (NDC) containing the payload camptothecin, is currently being clinically… 
2016
2016
Polymeric Nanoparticles and Cancer : Lessons Learnt from CRLX 101
CRLX101 (formerly IT-101) is a novel cyclodextrin-based polymer that selfassembles into nanoparticles. CRLX101 was designed to… 
2016
2016
CRLX101/Bevacizumab Combination No Better Than Standard Care in Metastatic RCC
The combination of bevacizumab and an investigational nanoparticle-drug conjugate known as CRLX101 failed to improve outcomes in… 
2016
2016
Abstract 1345: Tumor selective localization of CRLX101, an investigational nanoparticle-drug conjugate of camptothecin
CRLX101, an investigational nanoparticle-drug conjugate (NDC) containing the payload camptothecin, is currently being clinically… 
2015
2015
Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC).
TPS4579 Background: Up to 30% of pts. with RCC present with metastatic disease and 5-year survival among these pts. is less than… 
2013
2013
Abstract 2419: A phase Ib-IIa study evaluating the nanopharmaceutical CRLX101 in combination with bevacizumab in the treatment of patients (pts.) with advanced renal cell carcinoma.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background: Topoisomerase-1 (topo-1)-inhibiting… 
2013
2013
Abstract 376: CRLX101, a nanopharmaceutical in phase 2 clinical trials, is synergistic with antiangiogenic treatment through HIF-1α inhibition in an ovarian cancer xenograft model.
Antiangiogenic drugs reduce blood flow to tumors and thereby inhibit tumor growth by starving tumors of oxygen and nutrients… 
2012
2012
Serial Diffusion MRI to Monitor and Model Early Treatment Response to the Targeted Nanotherapy CRLX101
  • 2012
  • Corpus ID: 56020670
Targeted cancer nanotherapies are being developed to enhance local tumor therapeutic response. The nanotherapy CRLX101 (formerly… 
2011
2011
A Gene Expression Profile of BRCAness that Predicts for Responsiveness to Platinum and PARP Inhibitors
Abstract : Our results thus far support the hypothesis that the BRCAness profile is able to track diverse molecular mechanisms… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)